Age-Related Trends in Adults with Community-Onset Bacteremia

Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01050-17. doi: 10.1128/AAC.01050-17. Print 2017 Dec.

Abstract

To understand the epidemiological variation in bacteremia characteristics among differently aged populations, adults with community-onset bacteremia during a 6-year period were studied in a retrospective cohort. A total of 2,349 bacteremic patients were stratified into four age categories: young adults (18 to 44 years old; 196 patients; 8.3%), adults (45 to 64 years old; 707 patients; 30.1%), the elderly (65 to 84 years old; 1,098 patients; 46.7%), and the oldest old (85 years old; 348 patients; 14.8%). Age-related trends in critical illness (a Pitt bacteremia score of ≥4) at bacteremia onset, antibiotic-resistant pathogens (extended-spectrum β-lactamase [ESBL]-producing Escherichia coli, Klebsiella species, and Proteus mirabilis [EKP]; methicillin-resistant Staphylococcus aureus [MRSA]; and levofloxacin nonsusceptible EKP), inappropriate empirical antibiotic therapy (EAT), and 4-week mortality rate were observed. Using a multivariate regression model, critical illness at bacteremia onset (adjusted odds ratio [AOR], 9.03; P < 0.001) and inappropriate EAT (AOR, 2.67; P < 0.001) were the two leading predictors of 4-week mortality. Moreover, ESBL-producing EKP (AOR, 12.94; P < 0.001), MRSA (AOR, 8.66; P < 0.001), and levofloxacin-nonsusceptible EKP (AOR, 4.27; P < 0.001) were linked to inappropriate EAT. In conclusion, among adults with community onset bacteremia, significant positive age-related trends were noted in antibiotic-resistant pathogens and bacteremia severity, which were related to the increasing incidence of inappropriate EAT and 4-week mortality with age. Thus, different empirical antimicrobial regimens should be considered for distinct age groups.

Keywords: aging; appropriateness; bloodstream infections; community; empirical therapy.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Aging
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy*
  • Bacteremia / epidemiology*
  • Bacteremia / microbiology
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / microbiology*
  • Escherichia coli / drug effects
  • Female
  • Humans
  • Klebsiella pneumoniae / drug effects
  • Levofloxacin / therapeutic use
  • Male
  • Methicillin-Resistant Staphylococcus aureus / drug effects
  • Middle Aged
  • Proteus mirabilis / drug effects
  • Retrospective Studies
  • Young Adult
  • beta-Lactamases / metabolism

Substances

  • Anti-Bacterial Agents
  • Levofloxacin
  • beta-Lactamases